Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates

Nakastoev I.M.; Grachev A.E.; Gemdzhyan E.G.; Tsyba N.N.; Zhuravlev V.V.; Krechetova A.V.; Kastrikina I.S.; Vatagina E.A.; Ryzhko V.V.; Gorodetskiĭ V.M.

doi:https://doi.org/

Nakastoev I.M.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Grachev A.E.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Gemdzhyan E.G.

National Research Center for Hematology, Moscow, Russia

Tsyba N.N.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Zhuravlev V.V.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Krechetova A.V.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kastrikina I.S.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Vatagina E.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Ryzhko V.V.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Ministerstva zdravookhraneniia Rossiĭskoĭ Federatsii, Moskva

Gorodetskiĭ V.M.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates

Authors:

Nakastoev I.M., Grachev A.E., Gemdzhyan E.G., Tsyba N.N., Zhuravlev V.V., Krechetova A.V., Kastrikina I.S., Vatagina E.A., Ryzhko V.V., Gorodetskiĭ V.M.

More about the authors

Journal: Therapeutic Archive. 2013;85(8): 77‑80

Read: 2277 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Nakastoev IM, Grachev AE, Gemdzhyan EG, et al. Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates. Therapeutic Archive. 2013;85(8):77‑80. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Interleukin-6, cortisol, and brain-derived neurotrophic factor as biomarkers of the severity of traumatic brain injury and its complications in acute and long-term periods: results of a prospective study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):237-243

Comparison of Breast-Q scores following T-inverted augmentation mastopexy using split-thickness fascioglandular flap and standard technique: a prospective study. Plastic Surgery and Aesthetic Medicine. 2026;(2-2):29-34

Abstract:

Aim. To evaluate the effect of pathogen-inactivated platelet concentrates (PIPC) on posttransfusion platelet increments, hemorrhagic syndrome relief, and transfusion intervals. Subjects and methods. This prospective study included 29 hemoblastosis patients (13 women, 16 men), median age 38 years (20-66 years). Pathogens were inactivated by the photodynamic method using the Intecept system. Each patient received two PC transfusions: one PIPC transfusion and one control one. Posttransfusion platelet increments one hour and one day after PC transfusion, the course of hemorrhagic syndrome, and the time to next platelet transfusion were analyzed. Results. Pathogen inactivation with amotosalen and ultraviolet irradiation reduced posttransfusion platelet increments in recipients by 24% after one hour and by 29% after one day after PIPC transfusion versus control ones. Conclusion. The clinical efficiency of transfusions of amotosalen-induced PIPC was comparable with that of untreated platelet concentrates. Despite a reduction in post-transfusion platelet increment with the use of PIPC, this caused no significant increase in the frequency of transfusions.

Keywords:

platelet concentrate

pathogen inactivation

amotosalen

platelet increment

multivariate statistical analysis

prospective trial

Authors:

Nakastoev I.M.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Grachev A.E.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Gemdzhyan E.G.

National Research Center for Hematology, Moscow, Russia

Tsyba N.N.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Zhuravlev V.V.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Krechetova A.V.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kastrikina I.S.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Vatagina E.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Ryzhko V.V.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Ministerstva zdravookhraneniia Rossiĭskoĭ Federatsii, Moskva

Gorodetskiĭ V.M.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Close metadata

References:

Alter H.J. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22: 97-102.
Klein H.G., Anderson D., Bernardi M.J. et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338-2347.
Pogorelov V.M., Beskorovainova V.Yu., Gemdzhyan E.G. i dr. Adaptatsiya trombotsitopoeza donorov k protseduram trombotsitafereza. Gematol i transfuziol 2012; 3: 71.
Edwin R.M. Use of platelets in hospitals: factors that are driving up demand. NHS Blood and Transplant 2012; 8.
Cobain T.J., Vamvakas E.C., Wells A., Titlestad K. A survey of the demographics of blood use. Transfusion Med 2007; 17 (1): 1-15.
Garmaeva T.Ts., Kulikov S.M., Karyakin A.V. i dr. Monitorirovanie faktorov riska i indikatorov infitsirovannosti virusami gepatitov V i S gematologicheskikh bol'nykh. Gematol i transfuziol 2006; 1: 23-27
Vamvakas, E.C. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49: 2743-2758.
Stramer S.L., Hollinger F.B., Katz L.M. et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 (Suppl 2): 1S-236S.
Yarmonenko S.P., Vainson A.A. Radiobiologiya cheloveka i zhivotnykh. M: Vysshaya shkola 2004; 549.
Corash L. Virus inactivation in cellular components. Vox Sang 1996; 70 (Suppl. 3): 9-16.
McCullough J., Vesole D.H., Benjamin R.J. et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104 (5): 1534-1541.
Nakastoev I.M., Grachev A.E., Gemdzhyan E.G. i dr. Izmeneniya funktsional'nykh kharakteristik trombotsitov pri provedenii inaktivatsii patogenov v kontsentratakh trombotsitov. Gematol i transfuziol 2012; 5: 31-36
Goodrich R.P., Yerram N.R., Tay G.B. et al. Selective inactivation of viruses in the presence of human platelets: UV sensitization of psoralen derivatives. Proc Natl Acad Sci USA 1994; 91 (12): 5552-5556.
Snyder E., Raife T., Lin L. et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCI (S-59) and ultraviolet A light. Transfusion 2004; 44: 1732-1740.
Slichter S.J., Davis K., Enright H. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-4114.
Heddle N.M., Cook R.J., Tinmouth A. et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564-1573.
Murphy S., Snyder E., Cable R. et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006; 46 (1): 24-33.
Klein H.G., Anstee D.J. Mollison's Blood Transfusion in Clinical Medicine, 11th Edition. A revision of the 10th edition written by P.L. Mollison, C.P. Engelfriet and Marcela Contreras. Blackwell Publishing 2005: 623.
McCullough J., Vesole D.H., Benjamin R.J. et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-1541.
Chairman P.K. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.